Currently, in vivo brain markers in AD and MCI mainly include positron emission tomography scanning of amyloid, tau, and glucose metabolism, as well as brain structural imaging using MRI such as hippocampal atrophy [81]
Sinkus, R., Siegmann, K., Xydeas, T., Tanter, M., Claussen, C., & Fink, M
Clinical investigations with topical GHK-Cu formulations (concentration 0.1 to 0.3 percent) showed a measurable improvement in skin elasticity and skin density
\n\n\n\n BPC-157 Antidepressant and Anxiety Research in Animal Models \n\n\n\n Perhaps the most unexpected area of BPC-157 neurological research involves its interaction with dopaminergic and serotonergic neurotransmitter systems
The research continues to inform the development of next-generation selective GH analogs and metabolic modulators
Versus Steroids: Corticosteroids suppress inflammation but weaken tissue over time